Seulki Lee

Seulki Lee has extensive work experience in the biotech and pharmaceutical industry. Seulki is the Founder and CEO of D&D Pharmatech, a clinical-stage global biotech company focused on developing revolutionary medicines. In 2016, they also founded Neuraly, Inc., a clinical-stage company that translates neurology scientific discoveries into new drugs for neurodegenerative disorders. Seulki Lee is currently the CEO of Precision Molecular, Inc., a clinical-stage company developing imaging biomarkers and theranostics for CNS disorders and cancer. Seulki is also the Founder and CEO of Theraly Fibrosis, Inc., a preclinical-stage company developing treatments for fibrotic diseases. In 2019, Seulki Lee became the Executive Chairman of Valted Seq, Inc., which focuses on the discovery of neurodegenerative pathways and biomarkers. Prior to their entrepreneurial ventures, Seulki Lee was an Associate Professor of Radiology at the Johns Hopkins School of Medicine, where they conducted research on GLP-1 signaling in neurodegenerative disorders and TRAIL signaling in fibrosis diseases and cancer. Seulki also worked as a Group Leader of the Theranostic Nanomedicine Section at the NIH and as a Postdoctoral Fellow at Stanford University. Seulki Lee started their career as a Research Fellow at the Korea Institute of Science and Technology.

Seulki Lee earned their Doctor of Philosophy (Ph.D.) degree in Materials Science and Engineering from the Gwangju Institute of Science and Technology, where they studied from 2002 to 2006.